The effect of utilization of intravenous antibiotic for Mycobacterium abscessus on outcome of treatment

<bold>Introduction:</bold> Using of amikacin with macrolides for lung infection by Mycobacterium abscessus (MA) are recommended but other intravenous antibiotics have not been validated yet. <bold>Methods:</bold> A retrospective study on patients, who were admitted and treated for MA from 2010 to 2022; was conducted in our center. The effect of injectable agents on treatment outcome is observed. <bold>Results:</bold> Of the 285 enrolled non-tuberculosis mycobacteria infection diseases, 35 were diagnosed as MA. The mean age was 59.94+-15.97 and most of them were female (57%). The cure rate, death, and failure were 53%, 12%, and 6% respectively. Number of using betalactam was 14 and number of using amikacin was 23. The outcome of treatment did not associate with using of IV antibiotics significantly, however 67% of patients, who had good outcome; received IV antibiotics. None of the patients were HIV positive. <bold>Conclusions:</bold> In the recent study, using of IV antibiotics for MA was not correlated with favorable outcome of treatment. Susceptibility test for macrolides and amikacin should be available.